

[Abstract 30]

TREATMENT OF WALDENSTRÖM MACROGLOBULINEMIA WITH THE COMBINATION OF FLUDARABINE (FAMP) AND CYCLOPHOSPHAMIDE (CY): RESULTS IN 49 PATIENTS (PTS).

V Leblond, J Tamburini, V.Lévy, JP Femand, C. Chateilex, L. Stalniewicz, P. Morel, A. Delmer, F. Dreyfus, MJ. Grange, B. Christian. Hôpital Pitié- Salpêtrière, Paris, France.

Fludarabine is effective in Waldenström macroglobulinemia (WM) with a response rate of 30% in previously treated patients. The combination of fludarabine (FAMP) and cyclophosphamide (Cy) has been shown to be effective in chronic lymphoproliferative disorders. Based on these data, we have administered the combination of FAMP (25 mg/m² IV D1-D3) and Cy (300 mg/m² IV D1-D3) to 49 pts. The median age was 64 years (54-83). The median of hemoglobin, albumin, beta 2 microglobulin and IgM levels were 9.9g/100ml (4.6-14.9), 39.6 g/l (23-60.2), 3mg/l (1.4-7.6) and 24,7 g/l (2-71.3) respectively. 14 pts (29%) were previously untreated. FAMP/Cy was administered every 4 weeks for a median of 4 cycles. Partial response was defined by at least 50 % reduction of serum monoclonal protein and tumor infiltrate at all involved sites. 38/49 pts (77.6%) were in partial response, 9pts (18,9%) had a stable disease and 2 pts (4.1%) had a progressive disease. With a median of follow-up of 25 months, 10 pts relapsed and the median time to treatment failure was 27 months. The main toxicity was hematological: grade 3-4 anemia, neutropenia and thrombopenia were observed in 4, 14 and 20 courses respectively (total number of courses: 197). 12 pts died (6 from progression, 1 from a Richter, 1 from infection and 4 from a second malignancy). Event free survival and overall survival curves will be presented at the meeting. In a multivariate analysis, two factors badly influenced the overall and the event free survivals: age >65 yrs and IgM< 40g/l. The combination FAMP/Cy is efficient and with a high response rate even in previously treated patients with bad prognostic factors.